We are live on ! Find out more
GILD icon

Gilead Sciences

1,528 hedge funds and large institutions have $79.3B invested in Gilead Sciences in 2018 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 539 increasing their positions, 693 reducing their positions, and 72 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 72

21% more funds holding in top 10

Funds holding in top 10: 4757 (+10)

9% more capital invested

Capital invested by funds: $72.7B → $79.3B (+$6.6B)

0% more funds holding

Funds holding: 1,5231,528 (+5)

0.31% more ownership

Funds ownership: 79%79.31% (+0.31%)

22% less repeat investments, than reductions

Existing positions increased: 539 | Existing positions reduced: 693

27% less call options, than puts

Call options by funds: $1.21B | Put options by funds: $1.66B

Holders
1,528
Holders Change
+5
Holders Change %
+0.33%
% of All Funds
34.93%
Holding in Top 10
57
Holding in Top 10 Change
+10
Holding in Top 10 Change %
+21.28%
% of All Funds
1.3%
New
91
Increased
539
Reduced
693
Closed
72
Calls
$1.21B
Puts
$1.66B
Net Calls
-$449M
Net Calls Change
+$117M
Name Holding Trade Value Shares
Change
Change in
Stake
BFO
401
Boston Family Office
Massachusetts
$8.49M -$132K -1,742 -2%
CLOS
402
Compagnie Lombard Odier SCmA
Switzerland
$8.3M +$233K +3,084 +3%
BF
403
BOK Financial
Oklahoma
$8.29M -$1.02M -13,548 -11%
PHAM
404
Pacific Heights Asset Management
California
$8.26M
COPPSERS
405
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$8.21M -$2.25M -29,734 -22%
FIB
406
First Interstate Bank
Montana
$8.21M -$218K -2,886 -3%
UC
407
Unio Capital
New Jersey
$8.16M +$736K +9,751 +10%
CM
408
Castleark Management
Illinois
$8.15M -$75.5K -1,000 -0.9%
Connor, Clark & Lunn Investment Management (CC&L)
409
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$8.06M +$2.95M +39,075 +60%
WBC
410
Westpac Banking Corp
Australia
$8.04M +$65.6K +868 +0.8%
RIM
411
Redpoint Investment Management
Australia
$8.04M -$456K -6,032 -5%
RCM
412
Riverhead Capital Management
Delaware
$7.98M -$648K -8,586 -8%
ANI
413
American National Insurance
Texas
$7.96M
RIA
414
RPG Investment Advisory
California
$7.88M -$31.6K -419 -0.4%
IIM
415
Intact Investment Management
Quebec, Canada
$7.88M +$4.12M +54,600 +115%
BPB
416
Badgley, Phelps & Bell
Washington
$7.87M -$355K -4,705 -4%
EWM
417
Edge Wealth Management
New York
$7.86M +$344K +4,552 +5%
PPCM
418
Pillar Pacific Capital Management
California
$7.81M -$482K -6,385 -6%
Mariner
419
Mariner
Kansas
$7.79M +$790K +10,461 +12%
Natixis Advisors
420
Natixis Advisors
Massachusetts
$7.76M -$3.11M -41,137 -29%
MAM
421
Meeder Asset Management
Ohio
$7.73M +$441K +5,841 +6%
MCM
422
Masters Capital Management
Georgia
$7.72M -$21.4M -283,780 -74%
HVC
423
Healthcare Value Capital
New Jersey
$7.72M
UR
424
USCA RIA
Texas
$7.67M -$2.94M -38,915 -28%
MNBTD
425
Moody National Bank Trust Division
Texas
$7.66M +$6.83M +90,455 +1,031%

GILD Hedge Fund Activity: Q3 2018 in Review

1,528 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2018, worth a combined $79.3B — up 9.1% from $72.7B a quarter earlier.

Buyers outnumbered sellers: 91 funds opened new GILD positions and 72 closed out — a net gain of 19 holders — while 539 added to existing stakes and 693 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $968M. The largest seller was Parnassus Investments, cutting an estimated $683M.

  • 1,528 institutional investors held Gilead Sciences (GILD) as of Q3 2018, up from 1,523 in Q2 2018.
  • Funds reported $79.3B of Gilead Sciences stock for Q3 2018, up 9.1% quarter-over-quarter.
  • 91 funds opened new Gilead Sciences positions in Q3 2018 and 72 closed out, a net change of +19 holders.
  • The largest Gilead Sciences buyer in Q3 2018 was Capital Research Global Investors, an estimated $968M added.
  • The largest Gilead Sciences seller in Q3 2018 was Parnassus Investments, an estimated $683M sold.

Based on aggregated 13F filings for Q3 2018.